Skip to navigation Skip to content

Clinical Trial: High-Dose Biotin (MD1003)

Share

Details
Type of MS: PPMS|SPMS
Treatment mode of action: To protect nervous system
Number of Subjects: 600
Medication: High-Dose Biotin (MD1003)
Location: Arizona|California|Colorado|Connecticut|Florida|Illinois|Kansas|Maryland|Massachusetts|Michigan|Missouri|New Jersey|New Mexico|New York|North Carolina|Ohio|Oregon|Pennsylvania|Tennessee|Texas|Utah|Virginia|Washington
Institutions: Multiple, worldwide Contact Information
Dr. Robert Lasser, www.spi2study.com
617-378-8701

Funding:

MedDay

Description

Investigators worldwide are conducting a clinical trial testing high-dose biotin (MD1003, MedDay Pharmaceuticals SA) versus inactive placebo in 600 people with secondary or primary progressive MS. Participants can remain on existing disease-modifying treatments (such as ocrelizumab), if treatment has been stable for at least 90 days prior to enrollment. Please visit www.spi2study.com

Share